Pulnovo Medical

Executive Summary

Pulnovo Medical is a Chinese medical device company specializing in catheter-based therapies for pulmonary hypertension (PH) and heart failure. Its proprietary PADN (Pulmonary Artery Denervation) system uses radiofrequency ablation to disrupt sympathetic nerves around the pulmonary artery, reducing pulmonary artery pressure. Founded in 2013 and headquartered in Suzhou, China, the company has raised over $1 billion and employs 200–500 staff. With a commercial-stage presence, Pulnovo is targeting multiple PH subtypes and heart failure stages, positioning itself as a pioneer in interventional pulmonary vascular therapies. Given the large and growing patient population with PH and heart failure, Pulnovo's PADN technology addresses significant unmet needs. The company has established a strong foothold in China and is likely pursuing global expansion through regulatory approvals and clinical trials. With substantial funding and a focused pipeline, Pulnovo is well-positioned to capture market share. However, competition from established therapies and regulatory hurdles in Western markets remain key risks. Overall, the company's innovative approach and commercial progress justify a moderately high conviction score.

Upcoming Catalysts (preview)

• Q4 2026NMPA approval for expanded PH indication80% success
• Q2 2027CE mark or FDA IDE submission for PADN60% success
• Q3 2027Phase 3 heart failure trial results65% success